Your session is about to expire
← Back to Search
Neuromodulation Device
PoNS Therapy for Stroke Survivors
Phase 2 & 3
Recruiting
Research Sponsored by Helius Medical Inc
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up 12 week
Awards & highlights
No Placebo-Only Group
Summary
This trial aims to assess the safety and effectiveness of PoNS therapy in chronic stroke survivors. The study will also look at how PoNS therapy affects dynamic gait and balance, durability of effects, risk
Who is the study for?
This trial is for chronic stroke survivors who are experiencing issues with walking and balance. Participants should be able to commit to the study duration and follow-up requirements. Specific eligibility details aren't provided, but typically, trials exclude individuals with conditions that could interfere with the treatment or skew results.
What is being tested?
The trial is testing PoNS Therapy—a device aimed at improving gait and balance in people who have had a stroke. The study will look at safety, how well it works for walking and balance, its lasting effects, fall risks, adherence to using the device, and overall quality of life.
What are the potential side effects?
While specific side effects are not detailed here, safety is a primary focus of this trial. Generally speaking, neuromodulation devices like PoNS may cause discomfort or skin irritation where applied; other potential side effects would be monitored throughout the study.
Timeline
Screening ~ 3 weeks3 visits
Treatment ~ Varies
Follow Up ~ 12 week
Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~12 week
Treatment Details
Study Objectives
Study objectives can provide a clearer picture of what you can expect from a treatment.Primary study objectives
Primary safety endpoints
Awards & Highlights
No Placebo-Only Group
All patients enrolled in this study will receive some form of active treatment.
Trial Design
1Treatment groups
Experimental Treatment
Group I: Single ArmExperimental Treatment1 Intervention
open label administration of translingual neurostimulation.
Find a Location
Who is running the clinical trial?
Helius Medical IncLead Sponsor
9 Previous Clinical Trials
346 Total Patients Enrolled
Antonella Favit-VanPeltLead Sponsor
Share this study with friends
Copy Link
Messenger